Novavax's Arrival In Australia: When And What To Expect

The Novavax COVID-19 vaccine is the fourth vaccine to be approved for use in Australia, after Vaxzevria (AstraZeneca), Spikevax (Moderna), and Comirnaty (Pfizer). In early 2021, Australia agreed to purchase 51 million doses of the Novavax vaccine, which were expected to arrive in mid-2021. However, manufacturing delays and supply shortages pushed back the arrival date. In late 2021, the federal government expected the vaccines to arrive before the end of the year, but it is unclear if this occurred. In January 2022, it was announced that the Novavax vaccine would be available to Australians aged 18+ in the coming weeks, with samples set to arrive in early February for batch testing.

Explore related products

ViraFlexx Capsules Supplement, Vira Flexx Advanced Men Wellness Support, Official ViraFlex Maximum Strength Energy Performance, Vira Flex Premium Dietary Formula Reviews (60 Capsules)

$19.95

Novavax is the fourth COVID-19 vaccine approved for use in Australia

The Australian government had initially agreed to purchase 51 million doses of the Novavax vaccine from the US biotech company in early 2021. However, manufacturing delays and supply shortages slowed the process, pushing back the arrival of the vaccines. The Novavax vaccine is a "protein subunit vaccine", delivering only one part of the virus, specifically the spike protein found on the surface of the SARS-CoV-2 virus.

The Novavax vaccine is recommended to be administered in two doses, at least three weeks apart. It is available to Australians aged 18 and above through various avenues, including general practices, community pharmacies, Aboriginal Community Controlled Health Services, Commonwealth vaccination centres, and state and territory clinics. The TGA has approved the vaccine for primary vaccination courses, but studies for its use as a booster and in paediatric patients are ongoing.

The Novavax vaccine is expected to play a significant role in Australia's booster program, particularly for those who have already received a Pfizer, Moderna, or AstraZeneca vaccine. Its effectiveness and low side effects have been noted, and it is hoped that it will boost protection for individuals. The Novavax vaccine does not require ultra-low temperatures for storage and can be kept in refrigerators for up to three months.

The Novavax vaccine will be available through general practices, community pharmacies, and vaccination centres

The Novavax COVID-19 vaccine will be available to Australians through various avenues, including general practices, community pharmacies, and vaccination centres. This will ensure that individuals have convenient access to the vaccine and can choose the option that best suits their needs.

General practices will play a crucial role in administering the Novavax vaccine. Australians will be able to receive the vaccine from their trusted family doctors, who have already expressed interest in providing this service. This option may be particularly appealing to those who prefer the familiarity and comfort of their regular healthcare provider.

Community pharmacies will also offer the Novavax vaccine, providing another accessible and convenient option for individuals. Pharmacies are often easily accessible and have extended operating hours, making it convenient for people to get vaccinated at a time that suits their schedule.

Vaccination centres, including Commonwealth vaccination centres and state and territory clinics, will also be administering the Novavax vaccine. These centres have been specifically dedicated to vaccine rollout and have the infrastructure and resources to efficiently vaccinate a large number of people.

The availability of the Novavax vaccine through these diverse channels demonstrates the Australian government's commitment to making the vaccine accessible to as many people as possible. By offering multiple options, individuals can select the most suitable location and method for their vaccination, contributing to the country's overall vaccination rate and protection against COVID-19.

It is worth noting that the Novavax vaccine is the fourth COVID-19 vaccine approved for use in Australia, joining Vaxzevria (AstraZeneca), Spikevax (Moderna), and Comirnaty (Pfizer). The Australian government has purchased 51 million doses of the Novavax vaccine, and it is expected to play a significant role in the country's booster program.

Novavax is a protein subunit vaccine that delivers just one part of the SARS-CoV-2 virus

Novavax is a protein subunit vaccine, also known as a protein adjuvant vaccine. Unlike mRNA vaccines, it does not contain any part of the SARS-CoV-2 virus itself. Instead, it delivers just one part of the virus—the spike protein found on the surface of SARS-CoV-2. This spike protein is formulated as a nanoparticle, which cannot cause disease.

The Novavax vaccine uses a different mechanism to trigger an immune response compared to mRNA and vector vaccines. While other vaccines trick the body's cells into creating parts of the virus, Novavax contains the spike protein of the coronavirus itself. This spike protein is recognised as a foreign substance by the body's immune system, which then activates immune cells and produces antibodies to fight off what it thinks is an infection.

This process helps to protect against future infection with the SARS-CoV-2 virus. The immune system will be able to respond quickly and protect against COVID-19 if exposed to the actual virus in the future. Protein subunit vaccines have been used for years, including in whooping cough vaccines. They are safe and effective, and do not carry the risk of contracting COVID-19 or interacting with an individual's DNA.

The Novavax vaccine is given as two doses, administered in the upper arm muscle. It does not require ultra-low temperatures and can be stored in refrigerators for up to three months, making it easier to distribute. In Australia, Novavax is expected to be used mainly as a booster shot, following a primary vaccination with Pfizer, Moderna, or AstraZeneca.

The Novavax vaccine is predicted to be rolled out in Australia around September

The Novavax COVID-19 vaccine is the fourth vaccine to be approved for use in Australia, after Vaxzevria (AstraZeneca), Spikevax (Moderna), and Comirnaty (Pfizer). It is a "protein subunit vaccine", delivering only one part of the SARS-CoV-2 virus, instead of the entire virus.

At the beginning of 2021, Australia agreed to purchase 51 million doses of the Novavax vaccine. The vaccines were expected to arrive in mid-2021, but manufacturing delays and supply shortages slowed the company's progress. In October 2021, Novavax announced that it expected to complete its regulatory submissions in Australia "within the next couple of weeks". However, it was still unclear if Novavax supplies would reach Australia by the end of 2021.

In January 2022, it was announced that the Novavax vaccine would be available to Australians aged 18+ in the coming weeks, with samples set to arrive in Australia in early February for batch testing. The Novavax vaccine was recommended to be administered in two doses, at least three weeks apart.

Novavax is expected to play an important role in Australia's booster program

Novavax is the fourth COVID-19 vaccine to be approved for use in Australia, after Vaxzevria (AstraZeneca), Spikevax (Moderna), and Comirnaty (Pfizer). It is a "protein subunit vaccine", meaning it delivers only one part of the virus, specifically, the spike protein found on the surface of the SARS-CoV-2 virus. Novavax is a traditional protein-based vaccine that has demonstrated superior long-term efficacy and fewer side effects than mRNA vaccines.

The Novavax vaccine is expected to be particularly useful as a booster shot for those who have already received a first dose of a different vaccine. Professor Berry has stated that the use of a Novavax jab following a Pfizer, Moderna, or AstraZeneca vaccine could significantly boost an individual's protection. This is because mixing vaccine brands and platforms stimulates the immune system.

In early 2021, Australia agreed to purchase 51 million doses of the Novavax vaccine. However, manufacturing delays and supply shortages meant that the vaccines did not arrive as expected in mid-2021. It was then predicted that the Novavax vaccine would arrive in Australia in late 2021, but this was also delayed. Samples of the Novavax vaccines were set to arrive in Australia in early February 2022, with the vaccine available to be administered from the week of February 21, 2022.

Australians will be able to access the Novavax vaccine through general practices, community pharmacies, Aboriginal Community Controlled Health Services, Commonwealth vaccination centres, and state and territory clinics.

Frequently asked questions